GN’s Hearing division has reported 7% organic revenue growth in the third quarter of 2025 which it said was driven by continued strong performance of ReSound Vivia, enabling broad-based market share gains.
It said the divisional profit margin ended at 34%, driven by positive operating leverage but was partly offset by negative country mix.
“GN is exposed to an attractive hearing aid market, which has historically been growing 4%-6% in volumes driven by ongoing favourable demographic trends,” GN said in a statement on 6 November 2025.
“As a consequence of the slower beginning of the year driven by the uncertain macroeconomic environment, it is still expected that the market in 2025 will grow slower than its structural trend.
“Based on the strong sales momentum of ReSound Vivia and ReSound Savi, GN in 2025 expects to continue to gain market share. In the beginning of 2025, we assumed the Hearing division to contribute with organic revenue growth of 5% to 9%. Due to the lower market growth assumption, it is still assumed that the Hearing division will grow at the lower half of that range.”
ReSound Vivia and ReSound Savi launched in Australia and New Zealand in May 2025.
Mr Peter Karlströmer, CEO of GN Store Nord, said: “We are executing well across our priorities in markets currently growing below normal trends. The diversification of our manufacturing footprint progresses according to plan, and this together with commercial levers and cost control help us manage the tariff situation in line with our plans.
“We continue to see the benefits of our market-leading product portfolio, and remain excited about our innovation pipeline to support GN’s growth in the years to come.”
More reading
GN Hearing promotions for Paul Jones and Andreas Anderhov
GN launches its most intelligent hearing portfolio with world’s first Auracast assistant
